NASDAQ · Analyst Forecast

Estrella Immunopharma, Inc. (ESLA) Analyst Forecast

$0.99 NASDAQ: ESLA Market Cap $42.85M

Revenue and earnings estimates published by analysts covering Estrella Immunopharma, Inc. (ESLA), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Estrella Immunopharma, Inc., the average estimate for 2028 earnings per share is $-0.31; 1 analyst contribute to these figures. These are forecasts published by analysts, not results.

Revenue forecast (USD millions)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

Year	Low	Average	High	Analysts
2024	$0	$0	$0	1
2025	$0	$0	$0	1
2026	$0	$0	$0	1
2027	$0	$0	$0	1
2028	$0	$0	$0	1

Earnings per share forecast

Year	Low	Average	High	Analysts
2024	$-0.46	$-0.46	$-0.46	1
2025	$-0.72	$-0.72	$-0.72	1
2026	$-0.25	$-0.25	$-0.25	1
2027	$-0.32	$-0.32	$-0.32	1
2028	$-0.31	$-0.31	$-0.31	1

Estrella Immunopharma, Inc. (ESLA) forecast — frequently asked questions

What are analysts forecasting for Estrella Immunopharma, Inc.'s earnings?

The average analyst estimate for Estrella Immunopharma, Inc. (ESLA) earnings per share in 2028 is -0.31, with individual estimates between -0.31 and -0.31.

How much revenue is Estrella Immunopharma, Inc. expected to make?

Analysts forecast Estrella Immunopharma, Inc. (ESLA) revenue of $0 in 2028, based on 1 published estimates.

How many analysts cover ESLA?

1 analyst contribute estimates for Estrella Immunopharma, Inc. (ESLA). Thin coverage makes an average less reliable.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.